Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL921794 | 0.85 | MCHR1 (0.45) | SLC2A1KCNH2SIGMAR1MAPT | |
| SCHEMBL708599 | 0.85 | KCNH2 (0.43) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL920361 | 0.83 | KCNH2 (0.62) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL707691 | 0.82 | KCNH2 (0.40) | SLC2A1KCNH2KCNQ1CACNA1C | |
| SCHEMBL20995967 | 0.77 | CYP11B1 (0.47) | KCNH2HPGDS | |
| SCHEMBL20995965 | 0.77 | CYP11B1 (0.47) | KCNH2HPGDS | |
| SCHEMBL2688408 | 0.77 | KCNH2 (0.71) | KCNH2 | |
| SCHEMBL708298 | 0.75 | KCNH2 (0.77) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL921236 | 0.72 | KCNH2 (0.53) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL3357330 | 0.72 | KCNH2 (0.66) | KCNH2KCNQ1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-7875715-B2 | 6-[({1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; antibacteria; methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphylococci (MRCNS), penicillin-resistant Streptococcus pneumoniae | ASTRAZENECA AB (SE) | 2011-01-25 | — | — | US | disclosed |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | SLC2A1 3287/4885KCNH2 4242/4885KCNQ1 2681/4885 |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | SLC2A1 3287/4885KCNH2 4242/4885KCNQ1 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.